Wong Rebecca S Y, Cheong Soon-Keng
Faculty of Medicine, SEGi University, No. 9, Jalan Tecknologi, Taman Sains Selangor, Kota Damansara, PJU 5, 47810, Petaling Jaya, Selangor, Malaysia,
Clin Exp Med. 2014 Aug;14(3):235-48. doi: 10.1007/s10238-013-0247-4. Epub 2013 Jun 23.
Mesenchymal stem cells (MSCs) have captured the attention of researchers today due to their multipotent differentiation capacity. Also, they have been successfully applied clinically, in the treatment of various diseases of the heart and musculoskeletal systems, with encouraging results. Their supportive role in haematopoiesis and their anti-inflammatory and immunomodulatory properties have enhanced their contribution towards the improvement of engraftment and the treatment of graft-versus-host disease in patients receiving haematopoietic stem cell transplantation. However, there is a growing body of research that supports the involvement of MSCs in leukaemogenesis with several genetic and functional abnormalities having been detected in the MSCs of leukaemia patients. MSCs also exert leukaemia-enhancing effects and induce chemotherapy resistance in leukaemia cells. This paper addresses the key issues in the therapeutic value as well as the harmful effects of the MSCs in leukaemia with a sharp focus on the recent updates in the published literature.
间充质干细胞（MSCs）因其多能分化能力而受到当今研究人员的关注。此外，它们已成功应用于临床，用于治疗心脏和肌肉骨骼系统的各种疾病，并取得了令人鼓舞的结果。它们在造血过程中的支持作用以及抗炎和免疫调节特性，增强了它们对接受造血干细胞移植患者的植入改善和移植物抗宿主病治疗的贡献。然而，越来越多的研究支持MSCs参与白血病发生，在白血病患者的MSCs中检测到了几种遗传和功能异常。MSCs还发挥白血病增强作用，并诱导白血病细胞产生化疗耐药性。本文聚焦于已发表文献中的最新进展，阐述了MSCs在白血病治疗价值及有害影响方面的关键问题。
